Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-17-031484
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-05-11 14:02:39
Reporting Period:
2017-05-09
Filing Date:
2017-05-11
Accepted Time:
2017-05-11 14:02:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1510580 Kite Pharma Inc. KITE Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1609805 Ran Nussbaum C/o Kite Pharma, Inc.
2225 Colorado Avenue
Santa Monica CA 90404
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-05-09 3,520 $69.17 3,520 No 4 P Indirect See footnotes
Common Stock Acquisiton 2017-05-09 2,651 $69.17 2,651 No 4 P Indirect See footnotes
Common Stock Acquisiton 2017-05-09 1,029 $69.17 1,029 No 4 P Indirect See footnotes
Common Stock Acquisiton 2017-05-09 2,632 $68.94 2,632 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
No 4 P Indirect See footnotes
No 4 P Indirect See footnotes
No 4 P Indirect See footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,950 Direct
Footnotes
  1. The 7,200 shares acquired by the Pontifax entities were purchased in a block trade consisting of multiple transactions at prices ranging from $69.11 to 69.20, inclusive. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
  2. The securities are held in the name of Pontifax (Cayman) II L.P.
  3. The reporting person is a director of Pontifax Management 2 G.P. (2007) Ltd., which is the general partner of Pontifax Management II L.P., which is the general partner of Pontifax (Cayman) II, L.P., Pontifax (Israel) II, L.P. and Pontifax (Israel) II - Individual Investors, L.P.
  4. The securities are held in the name of Pontifax (Israel) II, L.P.
  5. The securities are held in the name of Pontifax (Israel) II - Individual Investors L.P.
  6. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $68.47 to $68.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
  7. The shares are held in the name of Magna 100 Ltd., of which the reporting person is President and Sultan.